Natco Pharma (NATCOPHARM)
Fast GrowerFairStock Score: 66/100 — STEADY
Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹903.15 |
| Market Cap | ₹16,176.31 Cr |
| P/E Ratio | 14.14 |
| ROCE | 32.78% |
| ROE | 20.47% |
| Dividend Yield | 0.72% |
| Profit Growth | -83.93% |
| Debt/Equity | 0.08 |
| Sales Growth | -48.5% |
| Free Cash Flow | ₹261 Cr |
| Promoter Holding | 49.48% |
| 52-Week Range | ₹774 — ₹1,224.1 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹514.92 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
I’m wearing Graham’s defensive-investor lens and Buffett’s quality lens. Natco at ₹903.15 with market cap ₹16,176 Cr looks statistically modest: P/E 14.14, P/B 1.75, book value ₹514.92. The business earns well on capital—ROE 20.47%, ROCE 32.78%—and carries almost no debt, D/E 0.08. Piotroski F-Score 8/9 and Altman Z-Score 3.33 suggest balance-sheet strength, while FCF of ₹261 Cr is positive. Five-year revenue CAGR of 18.26% shows it has grown over the cycle, and promoter holding at 49.48% aligns management with shareholders.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer